▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2647 by analyst upside · 2026-08-13
GSK
GSK plc
Healthcare · Market Cap $101B · P/E 16.0x
ANALYST PRICE TARGET
+15.5%
implied upside to consensus target
Current Price $50.3
Consensus Target $58.08
Bull Target $70.0
Bear Target $47.0
Analysts Covering 8
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
1
Hold
5
Sell
1
52-Week Low $38.62
52-Week High $61.7
YTD Return +3.1%
FUNDAMENTALS
Market Cap $101B
P/E Ratio (TTM) 16.0x
Forward P/E 9.8x
EPS (TTM) $3.14
PEG Ratio 105.18
Dividend Yield 3.57%
Revenue (TTM) $33.2B
Profit Margin 14.5%
52-WEEK RANGE
52-Week Low $38.62
52-Week High $61.7
Current Price $50.3
Bear Target $47.0
Bull Target $70.0
● Now $50.3 ● Target $58.08
TRADING DATA
Avg Volume 4.0M
YTD Return +3.1%
Analyst Count 8
Consensus Hold
Upside to Target +15.5%
Last Updated 2026-08-13

ANALYST SUMMARY

GSK plc (GSK) is currently trading at $50.3 with a Wall Street consensus price target of $58.08, implying potential upside of 15.5% over the next 12 months. 8 analysts currently cover GSK, with a consensus rating of Hold - 25% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $70.0, while the most cautious has a target of $47.0.

GSK operates in the Healthcare sector with a market capitalisation of $101B. The stock is up 3.1% year-to-date and is currently trading near the upper end of its 52-week range of $38.62 – $61.7.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ACAD +13.8%
ACADIA Pharmaceuticals Inc.
$5B · P/E 13.2x · Buy
INCY +3.5%
Incyte Corporation
$24B · P/E 15.4x · Buy
SNY +22.9%
Sanofi
$105B · P/E 23.2x · Hold
TCMD +56.1%
Tactile Systems Technology, Inc.
$555M · P/E 22.9x · Buy
OMCL +55.8%
Omnicell, Inc.
$2B · P/E 44.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GSK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ↓ Downgrade
Equal-Weight → Underweight 2026-01-06 Building track record
Jefferies ↓ Downgrade
Buy → Hold 2024-11-12 50% win rate (6 calls)
Guggenheim ↓ Downgrade
Buy → Neutral 2024-10-31 62% win rate (8 calls)
UBS ↓ Downgrade
Buy → Neutral 2024-07-08 33% win rate (6 calls)
Jefferies - Reiterated
Buy → Buy 2024-07-02 50% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
17/30
Consensus clarity
21/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →